Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study

Lesley M Arnold, Kenneth N Schikler, Lucinda Bateman, Tahira Khan, Lynne Pauer, Pritha Bhadra-Brown, Andrew Clair, Marci L Chew, Joseph Scavone, Pregabalin Adolescent Fibromyalgia Study Group, Anthony Alario, SushrutSudhir Babhulkar, Ramon Berenguer, Pamela Freeman, Jeffrey Gold, Steven Goodman, Hana Jarosova, Wendy Lee, Jonathan Liss, Svetlana Lvovich, Adonis Maiquez, Nabil Morcos, Shankara Nellikunja, Murray Passo, Laura Schanberg, VijaiPrakash Sharma, Charles Spencer, Mary Toth, SarathChandra Mouli Veeravalli, Wen-Chin Weng, Lesley M Arnold, Kenneth N Schikler, Lucinda Bateman, Tahira Khan, Lynne Pauer, Pritha Bhadra-Brown, Andrew Clair, Marci L Chew, Joseph Scavone, Pregabalin Adolescent Fibromyalgia Study Group, Anthony Alario, SushrutSudhir Babhulkar, Ramon Berenguer, Pamela Freeman, Jeffrey Gold, Steven Goodman, Hana Jarosova, Wendy Lee, Jonathan Liss, Svetlana Lvovich, Adonis Maiquez, Nabil Morcos, Shankara Nellikunja, Murray Passo, Laura Schanberg, VijaiPrakash Sharma, Charles Spencer, Mary Toth, SarathChandra Mouli Veeravalli, Wen-Chin Weng

Abstract

Background: Fibromyalgia (FM) is a common pain condition characterized by widespread musculoskeletal pain and tenderness. Pregabalin is an approved treatment for adults in the United States, but there are no approved treatments for adolescents with FM.

Methods: This was a 15-week, randomized, double-blind, placebo-controlled study and 6-month open-label safety trial of flexible-dose pregabalin (75-450 mg/day) for the treatment of adolescents (12-17 years) with FM. Primary outcome was change in mean pain score at endpoint (scored from 0-10, with 24-h recall). Secondary outcomes included global assessments and measures of pain, sleep, and FM impact.

Results: A total of 107 subjects were randomized to treatment (54 pregabalin, 53 placebo) and 80 completed the study (44 pregabalin, 36 placebo). Improvement in mean pain score at endpoint with pregabalin versus placebo was not statistically significant, treatment difference (95 % CI), -0.66 (-1.51, 0.18), P = 0.121. There were significant improvements with pregabalin versus placebo in secondary outcomes of change in pain score by week (P < 0.05 for 10 of 15 weeks); change in pain score at week 15 (1-week recall), treatment difference (95 % CI), -0.87 (-1.68, -0.05), P = 0.037; and patient global impression of change, 53.1 % versus 29.5 % very much or much improved (P = 0.013). Trends toward improvement with pregabalin in other secondary outcomes measuring pain, sleep, and FM impact were not significant. Safety was consistent with the known profile of pregabalin in adults with FM.

Conclusion: Pregabalin did not significantly improve the mean pain score in adolescents with FM. There were significant improvements in secondary outcomes measuring pain and impression of change.

Trial registrations: NCT01020474 ; NCT01020526 .

Keywords: Clinical trial; Juvenile fibromyalgia; Pain; Pregabalin.

Figures

Fig. 1
Fig. 1
Subject disposition. AE adverse event, FAS full analysis set, PPAS per protocol analysis set
Fig. 2
Fig. 2
Primary efficacy outcome and sensitivity analyses in the double-blind trial BOCF baseline observation carried forward, CI confidence interval, FAS full analysis set; LOCF last observation carried forward, mBOCF modified baseline observation carried forward (applying BOCF rule for subjects discontinued due to adverse events and LOCF rule for subjects discontinued due to any other reason); SE standard error. For the primary outcome the FAS was assessed, where missing data for week 15 mean pain score were imputed based on distribution of baseline pain scores if patients discontinued due to adverse events or abnormal laboratory test results or lack of efficacy; otherwise, if subjects discontinued due to other reasons, it was imputed based on distribution of post-baseline weekly mean pain scores using Markov chain Monte Carlo method. Mean (SD) pain score at baseline was 6.94 (1.23) with pregabalin and 6.95 (1.27) with placebo
Fig. 3
Fig. 3
Mean pain score by week in the double-blind trial. *P < 0.05 for pregabalin compared with placebo at each week
Fig. 4
Fig. 4
Patient global impression of change and parent global impression of change in the double-blind trial. Responders were those who were very much improved or much improved at endpoint. P values for pregabalin compared with placebo for each assessment. GIC Global impression of change

References

    1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19–28. doi: 10.1002/art.1780380104.
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–72. doi: 10.1002/art.1780330203.
    1. Kashikar-Zuck S, Lynch AM, Slater S, Graham TB, Swain NF, Noll RB. Family factors, emotional functioning, and functional impairment in juvenile fibromyalgia syndrome. Arthritis Rheum. 2008;59:1392–8. doi: 10.1002/art.24099.
    1. Kashikar-Zuck S, Lynch AM, Graham TB, Swain NF, Mullen SM, Noll RB. Social functioning and peer relationships of adolescents with juvenile fibromyalgia syndrome. Arthritis Rheum. 2007;57:474–80. doi: 10.1002/art.22615.
    1. Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states--maybe it is all in their head. Best Pract Res Clin Rheumatol. 2011;25:141–54. doi: 10.1016/j.berh.2011.02.005.
    1. Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, Starck LO, Keck PE., Jr Family study of fibromyalgia. Arthritis Rheum. 2004;50:944–52. doi: 10.1002/art.20042.
    1. Kashikar-Zuck S, Ting TV. Juvenile fibromyalgia: current status of research and future developments. Nat Rev Rheumatol. 2014;10:89–96. doi: 10.1038/nrrheum.2013.177.
    1. Kashikar-Zuck S, Cunningham N, Sil S, Bromberg MH, Lynch-Jordan AM, Strotman D, Peugh J, Noll J, Ting TV, Powers SW, et al. Long-term outcomes of adolescents with juvenile-onset fibromyalgia in early adulthood. Pediatrics. 2014;133:e592–600. doi: 10.1542/peds.2013-2220.
    1. Buskila D. Pediatric fibromyalgia. Rheum Dis Clin North Am. 2009;35:253–61. doi: 10.1016/j.rdc.2009.06.001.
    1. Buskila D, Press J, Gedalia A, Klein M, Neumann L, Boehm R, Sukenik S. Assessment of nonarticular tenderness and prevalence of fibromyalgia in children. J Rheumatol. 1993;20:368–70.
    1. Mikkelsson M, Sourander A, Piha J, Salminen JJ. Psychiatric symptoms in preadolescents with musculoskeletal pain and fibromyalgia. Pediatrics. 1997;100:220–7. doi: 10.1542/peds.100.2.220.
    1. Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P, Marina FF. Prevalence of fibromyalgia in children: a clinical study of Mexican children. J Rheumatol. 1998;25:2009–14.
    1. Zapata AL, Moraes AJ, Leone C, Doria-Filho U, Silva CA. Pain and musculoskeletal pain syndromes in adolescents. J Adolesc Health. 2006;38:769–71. doi: 10.1016/j.jadohealth.2005.05.018.
    1. Kashikar-Zuck S, Ting TV, Arnold LM, Bean J, Powers SW, Graham TB, Passo MH, Schikler KN, Hashkes PJ, Spalding S, et al. Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind, randomized, controlled clinical trial. Arthritis Rheum. 2012;64:297–305. doi: 10.1002/art.30644.
    1. Stephens S, Feldman BM, Bradley N, Schneiderman J, Wright V, Singh-Grewal D, Lefebvre A, Benseler SM, Cameron B, Laxer R, et al. Feasibility and effectiveness of an aerobic exercise program in children with fibromyalgia: results of a randomized controlled pilot trial. Arthritis Rheum. 2008;59:1399–406. doi: 10.1002/art.24115.
    1. Cymbalta® (duloxetine) (prescribing information) [URL: ]. Accessed 5 May 2016.
    1. Lyrica® (pregabalin) (prescribing information) [URL: ]. Accessed 5 May 2016.
    1. Savella® (milnacipran) (prescribing information) [URL: ]. Accessed 5 May 2016.
    1. Mariutto EN, Stanford SB, Kashikar-Zuck S, Welge JA, Arnold LM. An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia. J Clin Psychopharmacol. 2012;32:293–5. doi: 10.1097/JCP.0b013e31824858dc.
    1. Arnold LM, Bateman L, Palmer RH, Lin Y. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program. Pediatr Rheumatol Online J. 2015;13:27. doi: 10.1186/s12969-015-0025-9.
    1. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP, Jr, Sharma U, Martin SA, Barrett JA, Haig G. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792–805. doi: 10.1016/j.jpain.2008.03.013.
    1. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP, Jr, LaMoreaux LK, Martin SA, Sharma U. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–73. doi: 10.1002/art.20983.
    1. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Jr, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–14.
    1. Yunus MB, Masi AT. Juvenile primary fibromyalgia syndrome. A clinical study of thirty-three patients and matched normal controls. Arthritis Rheum. 1985;28:138–45. doi: 10.1002/art.1780280205.
    1. Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11:R120. doi: 10.1186/ar2783.
    1. Schanberg LE, Keefe FJ, Lefebvre JC, Kredich DW, Gil KM. Pain coping strategies in children with juvenile primary fibromyalgia syndrome: correlation with pain, physical function, and psychological distress. Arthritis Care Res. 1996;9:89–96. doi: 10.1002/1529-0131(199604)9:2<89::AID-ANR1790090204>;2-J.
    1. Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, Leon T, Zeiher B. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011;38:2643–52. doi: 10.3899/jrheum.110569.
    1. Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther. 2012;14:R217. doi: 10.1186/ar4056.
    1. Enck P, Klosterhalfen S, Weimer K, Horing B, Zipfel S. The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci. 2011;366:1889–95. doi: 10.1098/rstb.2010.0384.
    1. Arnold LM, Clauw DJ, Dunegan LJ, Turk DC. A framework for fibromyalgia management for primary care providers. Mayo Clin Proc. 2012;87:488–96. doi: 10.1016/j.mayocp.2012.02.010.
    1. Lobo CP, Pfalzgraf AR, Giannetti V, Kanyongo G. Impact of invalidation and trust in physicians on health outcomes in fibromyalgia patients. Prim Care Companion CNS Disord 2014;16:10.4088/PCC.
    1. Baiardi P, Giaquinto C, Girotto S, Manfredi C, Ceci A. Innovative study design for paediatric clinical trials. Eur J Clin Pharmacol. 2011;67(Suppl 1):109–15. doi: 10.1007/s00228-011-0990-y.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere